Table 4 Clinical trials on existing therapeutic modalities
Register No | Title | Phases | Disease | Interventions |
|---|---|---|---|---|
NCT06410924 | A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH | PHASE 2 | MASLD/MASH | Drug: DD01/ Placebo |
NCT06334666 | The Efficacy of Pedometer Motivated Physical Activity for the Management of Patients with MASLD | NA | MASLD/NAFLD Metabolic Syndrome Cardiovascular Disease (CVD) | Other: Encourage using a pedometer |
NCT06108219 | A Phase 2b, Study Evaluating Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) | PHASE 2 | NASH/MASH | Drug: Miricorilant/Placebo |
NCT06419374 | Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants with Compensated Cirrhosis Due to MASH | PHASE 3 | MASH/(NASH) With Compensated Cirrhosis | Biological: Pegozafern/Placebo |
NCT06138327 | A Study of BMN 255 in Participants with Non-Alcoholic Fatty Liver Disease and Hyperoxaluria | PHASE 1 | Hyperoxaluria NAFLD Kidney Stone | Drug: BMN 255 /Placebo |
NCT06121999 | Behavioral Lifestyle Intervention for MASLD in adults | NA | MASLD/MASH | Behavioral: Standard of care acceptance-based behavioral weight loss program/Occupational therapy dietary and lifestyle modifications |
NCT04283942 | Effect of Intermittent Calorie Restriction on MASLD Patients with Abnormal Glucose Metabolism | NA | Fatty Liver Disease Type 2 Diabetes | Behavioral: Intermittent calorie restriction (ICR) / Continuous calorie restriction (CCR) |
NCT05519475 | A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called NASH in Adult Participants at Increased Genetic Risk for This Condition | PHASE 2 | NASH/MASH | Drug: ALN-HSD / Placebo |
NCT06359444 | Effect of High-Intensity Exercise Rehabilitation on Liver Function and Insulin Sensitivity in Patients with MASLD (CENSORIAL) | NA | MASLD | Other: Combined aerobic + strength training /Combined strength + HIIT training |
NCT06318169 | A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants with MASH and Fibrosis (ENLIGHTEN-Fibrosis) | PHASE 3 | MASH/NASH With Fibrosis | Biological: Pegozafermin OTHER: Placebo |
NCT06220695 | A Nutrigenetic Intervention in MASLD | NA | NAFLD Fatty liver | Behavioral: Dietary intervention |
NCT06373523 | MASLD in Primary Hypothyroidism and Efficacy of Dapagliflozin | EARLY PHASE 1 | NAFLD Hepatic Steato-Fibrosis | Drug: Dapagliflozin 10 mg0mg Tab/ Placebo/ Levothyroxine Replacement daily |
NCT06461208 | A Prospective Fecal Microbiota Transplantation Trial to Improve Outcomes in Patients with Cirrhosis (PROMISE) | PHASE 3 | Liver Cirrhosis | Drug: Encapsulated FMT/Placebo |
NCT06352697 | Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adult MASLD Patients | NA | MASLD SLD Hepatic Steatosis | Dietary supplement: Probiotic lysate (postbiotic and metabiotic) / Placebo |
NCT06161571 | A Study Evaluating Efruxifermin in Subjects with Noninvasively Diagnosed NASH/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | PHASE 3 | NASH/MASH NAFLD/MASLD | Drug: Efruxifermin/Placebo |
NCT06352177 | Digital Therapeutic Lifestyle Intervention Program for Patients With MASLD | NA | NASH Liver Diseases | Other: Weight Application |
NCT06047847 | Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption | NA | MASLD | Dietary supplement: TOTUM-448 |